bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Table 2 from Prostate MRI: Evaluating Tumor Volume and Apparent Diffusion Coefficient as Surrogate Biomarkers for Predicting Tumor Gleason Score
Authors: Donati Olivio F. , Afaq Asim , Vargas Hebert Alberto , Mazaheri Yousef , Zheng Junting , Moskowitz Chaya S. , Hricak Hedvig , Akin Oguz
Published: April 2023

Lesion Characteristics.
Supplementary Table 3 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Authors: Hagleitner Melanie M. , Coenen Marieke J.H. , Gelderblom Hans , Makkinje Remco R. , Vos Hanneke I. , de Bont Eveline S.J.M. , van der Graaf Winette T.A. , Schreuder H.W. Bart , Flucke Uta , van Leeuwen Frank N. , Hoogerbrugge Peter M. , Guchelaar Henk-Jan , te Loo Dunja M.W.M
Published: April 2023

Supplementary Table 3. Genetic variants associated with 5-year PFS
Supplementary Table 1 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Authors: Hagleitner Melanie M. , Coenen Marieke J.H. , Gelderblom Hans , Makkinje Remco R. , Vos Hanneke I. , de Bont Eveline S.J.M. , van der Graaf Winette T.A. , Schreuder H.W. Bart , Flucke Uta , van Leeuwen Frank N. , Hoogerbrugge Peter M. , Guchelaar Henk-Jan , te Loo Dunja M.W.M
Published: April 2023

Supplementary Table 1. Set of 381 SNPs
Supplementary Tables S1-S9 from Clinically Relevant Molecular Subtypes in Leiomyosarcoma
Authors: Guo Xiangqian , Jo Vickie Y. , Mills Anne M. , Zhu Shirley X. , Lee Cheng-Han , Espinosa Inigo , Nucci Marisa R. , Varma Sushama , Forgó Erna , Hastie Trevor , Anderson Sharon , Ganjoo Kristen , Beck Andrew H. , West Robert B. , Fletcher Christopher D. , van de Rijn Matt
Published: April 2023

Supplementary Tables S1-S9. Table S1: Clinicopathological characterization of 99 Leiomyosarcoma cases; Table S2: Patient clinical features for TCGA dataset (N=82); Table S3: The number of overlapping genes by SAMSeq analysis between 3SEQ and TCGA RNASEQ datasets; Table S4: Comparison of expression profiles between TCGA subtypes with SAMSeq; Table S5: SAMSeq results between different LMS subtypes in 3SEQ data; Table S6: Enriched GO biological processes (BP) terms by genes over-expressed in each LMS subtype; Table S7: IHC scoring results for protein LMOD1 and ARL4C on LMS cases analysed by 3SEQ; Table S8: Univariate and multivariate analysis of different subtypes of LMS defined by IHC staining and other factors; Table S9: Patient characteristics on TAâ€�201 (N=127).
Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
Authors: Wu David , Emerson Ryan O. , Sherwood Anna , Loh Mignon L. , Angiolillo Anne , Howie Bryan , Vogt Jennifer , Rieder Mark , Kirsch Ilan , Carlson Christopher , Williamson David , Wood Brent L. , Robins Harlan
Published: April 2023

Supplementary Figure 2. Amplification bias across iterative primer mix optimization. The PCR amplification bias (proportional representation, relative to mean) of each of our synthetic templates (1,116 for IGH) was calculated for an equimolar mix of forward and reverse primers, with a final optimized primer mix, and after computational normalization (these results are from a subsequent experiment, not the one used to derive computational normalization factors). The calculated dynamic range and interquartile range of PCR bias, and sum of squared log (PCR bias) values are shown for each primer mix. Modification of multiplex primer concentrations followed by computational normalization is an effective way to minimize PCR bias even in complex multiplexed assays.
Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
Authors: Wu David , Emerson Ryan O. , Sherwood Anna , Loh Mignon L. , Angiolillo Anne , Howie Bryan , Vogt Jennifer , Rieder Mark , Kirsch Ilan , Carlson Christopher , Williamson David , Wood Brent L. , Robins Harlan
Published: April 2023

Supplementary Figure 5. Example of evolved clonotypes in one patient. To illustrate the dynamics of evolved clonotypes, a patient with MRD at day 29 (index clone persists at 0.76% with a large number of VH-replaced variants of the index clone) is shown. For each time point (Pre-treatment, x-axis and Day 29 post-treatment, y-axis), this plot shows the fraction of the total clone size (major clone plus evolved clonotypes) accounted for by each clonotype. Each data point represents a different clonotype. 1,607 evolved versions of the index clone were seen only in the pre-treatment sample, and 112 versions were seen only in the post-treatment sample; these are shown in red. 24 evolved clonotypes were seen at both time points, and these are shown in blue. The index clone at diagnosis is shown as a black data point (top right).
Supplementary Figure 1 from Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer
Authors: Pan Ke , Guan Xun-Xing , Li Yong-Qiang , Zhao Jing-Jing , Li Jian-Jun , Qiu Hui-Juan , Weng De-Sheng , Wang Qi-Jing , Liu Qing , Huang Li-Xi , He Jia , Chen Shi-Ping , Ke Miao-La , Zeng Yi-Xin , Xia Jian-Chuan
Published: April 2023

PDF file - 108KB, CIK cell treatment protocol.
Supplementary Experimental Procedures, Supplementary Figures 1-7, Supplementary Tables 1-2 from B7-H4(B7x)–Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Authors: Yao Yu , Ye Hongxing , Qi Zengxin , Mo Lianjie , Yue Qi , Baral Aparajita , Hoon Dave S.B. , Vera Juan Carlos , Heiss John D. , Chen Clark C. , Hua Wei , Zhang Jianmin , Jin Kunlin , Wang Yin , Zang Xingxing , Mao Ying , Zhou Liangfu
Published: April 2023

Supplementary Figure 1. Expression of B7-H4 in GBM from TCGA database. Supplementary Figure 2. WB analysis of GIMs, normal microglia, Model GL261 and Vitro GL261 Supplementary Figure 3. IL-6 and IL-10 expression pattern in serum, CSF, and the glioma microenvironment. Supplementary Figure 4. WB analysis of BV2 microglia stimulated with CD133+ supernatant Supplementary Figure 5. IL-6/Stat3/B7-H4 signal transduction pathway. Supplementary Figure 6. GIMs enriched from CD133+ cells induced inhibition of T cell function via B7-H4 in vitro. Supplementary Figure 7. Outline for the increase of B7-H4 expression by immunosuppressive cross talk between CD133+ cells and GIMs. Supplementary Table 1. Clinical characteristics of the patients for serum, CSF and tissue Supplementary Table 2. Clinical characteristics of the new diagnosed GBM patients for survival analysis
Related Article from Establishing a Diagnostic Road Map for MUTYH-Associated Polyposis
Authors: Borras Ester , Taggart Melissa W. , Lynch Patrick M. , Vilar Eduardo
Published: April 2023

Related Article from Establishing a Diagnostic Road Map for MUTYH-Associated Polyposis
Legend for supplementary Figure S1 from Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
Authors: Wozniak Agnieszka , Rutkowski Piotr , Schöffski Patrick , Ray-Coquard Isabelle , Hostein Isabelle , Schildhaus Hans-Ulrich , Le Cesne Axel , Bylina Elzbieta , Limon Janusz , Blay Jean-Yves , Siedlecki Janusz A. , Wardelmann Eva , Sciot Raf , Coindre Jean-Michel , Debiec-Rychter Maria
Published: April 2023

Legend for supplementary Figure S1
Figure S2 from Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Authors: Whatcott Clifford J. , Diep Caroline H. , Jiang Ping , Watanabe Aprill , LoBello Janine , Sima Chao , Hostetter Galen , Shepard H. Michael , Von Hoff Daniel D. , Han Haiyong
Published: April 2023

Figure S2. Quantitative assessment of stromal markers, including α-SMA, Col III, Col IV, and HA, in primary tumors and a small cohort of metastatic lesions (n=20).
Supplementary Figure S2. Reproducible measurement of CEA mRNA by serial dilution of MKN45. from Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial
Authors: Yamamoto Hirofumi , Murata Kohei , Fukunaga Mutsumi , Ohnishi Tadashi , Noura Shingo , Miyake Yasuhiro , Kato Takeshi , Ohtsuka Masahisa , Nakamura Yurika , Takemasa Ichiro , Mizushima Tsunekazu , Ikeda Masataka , Ohue Masayuki , Sekimoto Mitsugu , Nezu Riichiro , Matsuura Nariaki , Monden Morito , Doki Yuichiro , Mori Masaki
Published: April 2023

The standard curves were plotted using the serial dilution of cDNA from MKN45. We confirmed that the CEA value was reproducibly measured in the range of 1.0x10-1 to 1.0x10-4 with standard deviation < 10% in each dilution.
Supplementary Methods from Targeting Cancer Cells via the Reactive Oxygen Species-Mediated Unfolded Protein Response with a Novel Synthetic Polyphenol Conjugate
Authors: Shin Soon Young , Lee Jong Min , Lee Mi So , Koh Dongsoo , Jung Hyeryoung , Lim Yoongho , Lee Young Han
Published: April 2023

PDF file - 112K
Supplementary Data 2 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

XLSX file - 15K, Gene IDs for gene signatures developed from unsupervised hierarchical clustering.
Supplementary Data 1 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

XLSX file - 36K, TCGA sample IDs and genomic subtype of mRNA-seq breast and ovarian data.
Supplementary Table S1 from Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome
Authors: Deckers Ivette A.G. , Schouten Leo J. , Van Neste Leander , van Vlodrop Iris J.H. , Soetekouw Patricia M.M.B. , Baldewijns Marcella M.L.L. , Jeschke Jana , Ahuja Nita , Herman James G. , van den Brandt Piet A. , van Engeland Manon
Published: April 2023

Primer sequences and PCR conditions used to analyze promoter methylation of CDO1 in a population-based series of clear-cell renal cancer patients - the Netherlands Cohort Study, 1986-2006.
Supplemental material from MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Authors: Rovira Jordina , Karube Kennosuke , Valera Alexandra , Colomer Dolors , Enjuanes Anna , Colomo Lluís , Martínez-Trillos Alejandra , Giné Eva , Dlouhy Ivan , Magnano Laura , Delgado Julio , Martínez Antonio , Villamor Neus , Campo Elías , López-Guillermo Armando
Published: April 2023

1 - Serum and tumor cytokines according to MYD88 mutational status 2- Discrepancies in cell of origin distribution between gene expression and immunohistochemistry
Supplementary Table 2 from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Supplementary Table 2. Proteins identified in MMECs upon treatment with SU11274 or SU11274 plus bortezomib or plus lenalidomide (MALDI-TOF/TOF mass spectrometry).
Supplemental Table 3 from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

KPC and KPTC Secretomes
Supplementary Figure S2 from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Supplementary Figure S2. SU11274 dose finding.
Supplemental Figure 2 from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

Characterization of lung metastases in KPC and KPTC mice.
Supplemental Figure 1 revised from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

Genotyping of Mice and Features of PanINs.
Supplementary Tables from Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases
Authors: Guidetti Anna , Carlo-Stella Carmelo , Locatelli Silvia L. , Malorni Walter , Mortarini Roberta , Viviani Simonetta , Russo Domenico , Marchianò Alfonso , Sorasio Roberto , Dodero Anna , Farina Lucia , Giordano Laura , Di Nicola Massimo , Anichini Andrea , Corradini Paolo , Gianni Alessandro M.
Published: April 2023

Supplementary Tables. Includes 4 tables: a) Supplementary Table 1 describing clinical characteristics of all HL patients b) Supplementary Table 2 describing disease characteristics of HL responding patients c) Supplementary Table 3 describing adverse events observed during the month of therapy with perifosine alone d) Supplementary Table 4 describing association of serum soluble cytokine levels with therapy response
Supplementary Materials and Methods, Tables 1 - 8 from A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma
Authors: Nadal Ernest , Zhong Jinjie , Lin Jules , Reddy Rishindra M. , Ramnath Nithya , Orringer Mark B. , Chang Andrew C. , Beer David G. , Chen Guoan
Published: April 2023

PDF file - 147KB, Additional Material and Methods. Table S1- Clinicopathological characteristics of the 151 lung AC patients. Table S2- Differentially expressed miRs between lung adenocarcinoma and matched nonmalignant lung samples. Table S3- MiRs significantly associated with the presence of solid or lepidic-mucinous invasive component in the tumor. Table S4- Survival analysis based on clinicopathological characteristics. Table S5- Statistically significant miRs in the univariate and multivariate Cox regression for OS. Table S6- DFS and OS analysis (Multivariate Cox model) of risk score in the validation set. Table S7- Gene Ontology terms based upon the transcripts significantly correlated with miR-370, miR-411 and miR-376a expression in 51 lung ACs. Table S8- EMT genes significantly correlated with miR-411 expression in 51 lung ACs.
S7: Additional material and methods from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Authors: Verreault Maite , Schmitt Charlotte , Goldwirt Lauriane , Pelton Kristine , Haidar Samer , Levasseur Camille , Guehennec Jeremy , Knoff David , Labussière Marianne , Marie Yannick , Ligon Azra H. , Mokhtari Karima , Hoang-Xuan Khê , Sanson Marc , Alexander Brian M. , Wen Patrick Y. , Delattre Jean-Yves , Ligon Keith L. , Idbaih Ahmed
Published: April 2023

Extraction from tumor cells, frozen tumor tissue and formalin fixed paraffin embedded (FFPE) tumor tissue; MDM2 gene copy number and TP53 mutational statuses; MDM2 gene copy number and TP53 mutational statuses; Western blot; Immunostaining in tumor or tissue cells
Supplementary Figure 4 from Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Authors: Cook Katherine L. , Wärri Anni , Soto-Pantoja David R. , Clarke Pamela AG. , Cruz M. Idalia , Zwart Alan , Clarke Robert
Published: April 2023

Circulating mouse cytokine and chemokine involvement. A. ELISA analysis of IL-1ÃƒÆ’Ã…Â½Ãƒâ€šÃ‚Â², IL-3, IL-4, IL-5, IL-6, IL-12p70, and IL-17 from mice treated with control, CQ, ICI, ICI+CQ, TAM, and TAM+CQ. n=3-6
Supplementary Figure 3 from Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Authors: Cook Katherine L. , Wärri Anni , Soto-Pantoja David R. , Clarke Pamela AG. , Cruz M. Idalia , Zwart Alan , Clarke Robert
Published: April 2023

Antiestrogens effect angiogenesis. A. LCC9 cells were treated with vehicle, 1 ÃƒÆ’Ã…Â½1/4M CQ, 100 nM ICI, or 100 nM TAM for 72 hours and protein homogenates were collected. Western blot hybridization was used to confirm levels of pVEGFR2 and total VEGFR2. Gel loaded was confirmed by ÃƒÆ’Ã…Â½Ãƒâ€šÃ‚Â²-actin. n=3, *p<0.05. B. Blood vessel diameter was calculated from LCC9 CD31 stained tumor sections using Image J. n=3, in triplicate, *p<0.05
Supplemental Table 1 from Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Authors: Carvajal Richard D. , Lawrence Donald P. , Weber Jeffrey S. , Gajewski Thomas F. , Gonzalez Rene , Lutzky Jose , O'Day Steven J. , Hamid Omid , Wolchok Jedd D. , Chapman Paul B. , Sullivan Ryan J. , Teitcher Jerrold B. , Ramaiya Nikhil , Giobbie-Hurder Anita , Antonescu Cristina R. , Heinrich Michael C. , Bastian Boris C. , Corless Christopher L. , Fletcher Jonathan A. , Hodi F. Stephen
Published: April 2023

Supplemental Table 1. Adverse events observed and adjudicated as possibly, probably or definitely related to therapy (n = 19).
Table 1.Detailed description of dose and schedule developed and toxicity reported in phase I and registration trials for each SM-MTA. from Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Authors: Roda Desamparados , Jimenez Begoña , Banerji Udai
Published: April 2023

Detailed description of phase I and registration trials for each approved small molecule. Dose and schedule developed will be specified, along with dose modifications due to toxicity.
Supplementary Materials and Methods from Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Authors: Wainwright Derek A. , Chang Alan L. , Dey Mahua , Balyasnikova Irina V. , Kim Chung Kwon , Tobias Alex , Cheng Yu , Kim Julius W. , Qiao Jian , Zhang Lingjiao , Han Yu , Lesniak Maciej S.
Published: April 2023

PDF file - 94KB
Supplementary Table S4 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Alves Carla L. , Elias Daniel , Lyng Maria , Bak Martin , Kirkegaard Tove , Lykkesfeldt Anne E. , Ditzel Henrik J.
Published: April 2023

ER status in primary tumors and metastasis of ER+ advanced breast cancer patients treated or not with fulvestrant in the advanced disease setting.
Supplementary Table S3 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Alves Carla L. , Elias Daniel , Lyng Maria , Bak Martin , Kirkegaard Tove , Lykkesfeldt Anne E. , Ditzel Henrik J.
Published: April 2023

Clinical and pathological characteristics of ER+ advanced breast cancer patients according to CDK6 expression levels.
Suppl. Fig. 4 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
Authors: Sharma Ashish , Bender Sabine , Zimmermann Martina , Riesterer Oliver , Broggini-Tenzer Angela , Pruschy Martin N.
Published: April 2023

The proprotein convertase furin mediates IR-induced ADAM17 activation.
Supplementary Figure 4 from Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer
Authors: Chan Alison , Prassas Ioannis , Dimitromanolakis Apostolos , Brand Randall E. , Serra Stefano , Diamandis Eleftherios P. , Blasutig Ivan M.
Published: April 2023

Supplementary Figure 4. Correlation plot of log10 CA125 and log10 CUZD1 with the linear trend line and equation.
Supplemental Fig.5 from miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Authors: Yang Yijun , Li Fei , Saha Manujendra N. , Abdi Jahangir , Qiu Lugui , Chang Hong
Published: April 2023

Supplemental Fig.5. Synthetic miR-197 retards tumor growth and prolongs survival in human MM xenograft models
Supplemental Fig.2 from miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Authors: Yang Yijun , Li Fei , Saha Manujendra N. , Abdi Jahangir , Qiu Lugui , Chang Hong
Published: April 2023

Supplemental Fig.2. Expression of miR-553 and its effect on MM cells
Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Table 2 Pharmacokinetic parametersa of irinotecan and its main active metabolite SN-38 when irinotecan was administered as a 1.5-h intravenous infusion (100 mg/m2) alone on cycle 1 day 1 or in combination with veliparib on cycle 2 day 8
Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Table 1 Pharmacokinetic parametersa of veliparib and its main metabolite (A- 925088) when veliparib was given orally alone on cycle 2 day -1 or in combination with irinotecan on cycle 2 day 8
Supplementary Table S2 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplementary Table S2. Kras and EGFR mutations and EGFR expression according to RhoB expression in tumors
Supplementary Figure S4 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplementary Figure S4. Representative images of healthy lungs and lung tumors from EGFR/rhob mice stained with CD34 antibody, and corresponding quantification
Supplementary Figure S2 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplementary Figure S2. Western blot of RhoB and EGFRL858R from protein lysate of healthy lungs and lung tumors from EGFR/rhob mice, with corresponding quantification of RhoB protein level; Representative microscopic view of H&E-stained or EGFRL858R or Ki-67-stained healthy and tumor mouse lungs
supplementary figure 4 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary figure 4. MDSC Chemotaxis induction by autologous patient serum. chemotactic migration of the indicated MDSC subsets or dextran-purified PMN from cancer patients in response to autologous serum or serum from healthy volunteers. Statistical comparisons were made by U-Mann-Whitney tests.
Supplemental Tables S1-2 from A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma
Authors: de Baaij Laura R. , Berkhof Johannes , van de Water Jolanda M.W. , Sieniawski Michal K. , Radersma Marijn , Verbeek Wieke H.M. , Visser Otto J. , Oudejans Joost J. , Meijer Chris J.L.M. , Mulder Chris J.J. , Lennard Anne L. , Cillessen Saskia A.G.M.
Published: April 2023

Supplemental Tables S1-2. Supplementary Table S1 shows the phenotype of the included EATLs. Supplementary Table S2 demonstrates the development of the model by cross validation after applying the bootstrap method
Movie S1 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Authors: Luo Haiming , England Christopher G. , Shi Sixiang , Graves Stephen A. , Hernandez Reinier , Liu Bai , Theuer Charles P. , Wong Hing C. , Nickles Robert J. , Cai Weibo
Published: April 2023

Movie S1 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Supplemental Data from MACC1 Induces Tumor Progression in Transgenic Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4
Authors: Lemos Clara , Hardt Markus S. , Juneja Manisha , Voss Cynthia , Förster Susann , Jerchow Boris , Haider Wolfram , Bläker Hendrik , Stein Ulrike
Published: April 2023

Material and Methods Table 1. Primers for genotyping vil-MACC1 mice Table 2. Primers for qRT-PCR Table 3. Primers for ChIP Table 4. The 50 most upregulated genes when comparing Apc vs vil-MACC1/ApcMin mice Table 5. The 50 most downregulated genes when comparing Apc vs vil-MACC1/ApcMin mice Supplementary Figure legends.
Supplementary Tables S1-S2, S4-S5 from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Tables S1-S2, S4-S5. Supplementary Table S1: The fingerprints of HCC78 and HCC78CR1-3 cells. Supplementary Table S2: Primers used for RT-PCR, gene amplification, and qPCR. Supplementary Table S4: The expression of EGFR and its ligand by RNA-seq. Supplementary Table S5: RNA-seq pathway enrichment analysis of differentially expressed genes.
Supplementary Figures S5-S6 from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Figures S5-S6. Supplementary Figure S5: The relative mRNA expression levels of HB-EGF and EGFR and cell viability assay in HCC78 cells treated with/without HB-EGF or EGF. Supplementary Figure S6: Cell viability assays in HCC78 and HCC78CR1-3 cells treated with cetuximab and gefitinib.
Supplementary Figures S1-S2 from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Figures S1-S2. Supplementary Figure S1: ROS1 fusion transcripts expressed in HCC78 cells and Patients. Supplementary Figure S2: Colony formation assay of ROS1-mutant forms and cell viability assays of HCC78 and HCC78CR1-3 cells.
Table S2 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

Genes used in development of the recurrence risk score assay.
Supplementary Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Authors: Ortiz-Cuaran Sandra , Scheffler Matthias , Plenker Dennis , Dahmen llona , Scheel Andreas H. , Fernandez-Cuesta Lynnette , Meder Lydia , Lovly Christine M. , Persigehl Thorsten , Merkelbach-Bruse Sabine , Bos Marc , Michels Sebastian , Fischer Rieke , Albus Kerstin , König Katharina , Schildhaus Hans-Ulrich , Fassunke Jana , Ihle Michaela A. , Pasternack Helen , Heydt Carina , Becker Christian , Altmüller Janine , Ji Hongbin , Müller Christian , Florin Alexandra , Heuckmann Johannes M. , Nuernberg Peter , Ansén Sascha , Heukamp Lukas C. , Berg Johannes , Pao William , Peifer Martin , Buettner Reinhard , Wolf Jürgen , Thomas Roman K. , Sos Martin L.
Published: April 2023

Supplementary figure legends
Figure S6 from A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cell Carcinoma
Authors: Hazar-Rethinam Mehlika , de Long Lilia Merida , Gannon Orla M. , Topkas Eleni , Boros Samuel , Vargas Ana Cristina , Dzienis Marcin , Mukhopadhyay Pamela , Simpson Fiona , Endo-Munoz Liliana , Saunders Nicholas A.
Published: April 2023

Figure S6. Inhibition of Sphk1 sensitizes FaDu cells to the cytotoxic actions of doxorubicin in vitro and in vivo.
Supplementary Methods and figure legends from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Supplementary Methods and figure legends. Supplementary methods and legends for supplementary figures
Supplemental Table from RETRACTED: Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Supplemental Table
Suppl Fig 6 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 6. Mechanism of synergy of BEZ235 plus dexamethasone.
Supplemental Figure S2 from Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Migration, invasion, and expression of EMT proteins.
Supplementary Data - Tracked from Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Authors: Santiago-Walker Ademi , Gagnon Robert , Mazumdar Jolly , Casey Michelle , Long Georgina V. , Schadendorf Dirk , Flaherty Keith , Kefford Richard , Hauschild Axel , Hwu Patrick , Haney Patricia , O'Hagan Anne , Carver Jennifer , Goodman Vicki , Legos Jeffrey , Martin Anne-Marie
Published: April 2023

Supplementary Figure S1. Distribution of BRAF V600E cfDNA mutation fraction across study samples; Supplementary Figure S2. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplementary Table S1. Baseline clinical characteristics; Supplementary Table S2. Correlation between cfDNA mutation fraction, baseline tumor burden (SLD), and LDH; Supplementary Table S3. Association between cfDNA mutation fraction, with baseline covariates; Supplementary Table S4. Association between cfDNA mutation status, with baseline covariates; Supplementary Table S5. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplementary Table S6. cfDNA mutation fraction independently predicts PFS and OS in patients with baseline tumor V600E mutations
Supplemetary Methods from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Authors: Thomas Anish , Rajan Arun , Szabo Eva , Tomita Yusuke , Carter Corey A. , Scepura Barbara , Lopez-Chavez Ariel , Lee Min-Jung , Redon Christophe E. , Frosch Ari , Peer Cody J. , Chen Yuanbin , Piekarz Richard , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Schrump David S. , Giaccone Giuseppe
Published: April 2023

Supplemetary Methods from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Figure S3 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Authors: Casagrande Naike , Celegato Marta , Borghese Cinzia , Mongiat Maurizio , Colombatti Alfonso , Aldinucci Donatella
Published: April 2023

Figure S3. Cisplatin activity in SKOV3 spheroids and OVCAR5 tumor xenograft
Figure S2 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Authors: Casagrande Naike , Celegato Marta , Borghese Cinzia , Mongiat Maurizio , Colombatti Alfonso , Aldinucci Donatella
Published: April 2023

Figure S2. Cisplatin activity in A2780, A2780cis and OVCAR5 cells
Supplementary Figure S7qc and S8qc from Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Authors: Reinartz Roman , Wang Shanshan , Kebir Sied , Silver Daniel J. , Wieland Anja , Zheng Tong , Küpper Marius , Rauschenbach Laurèl , Fimmers Rolf , Shepherd Timothy M. , Trageser Daniel , Till Andreas , Schäfer Niklas , Glas Martin , Hillmer Axel M. , Cichon Sven , Smith Amy A. , Pietsch Torsten , Liu Ying , Reynolds Brent A. , Yachnis Anthony , Pincus David W. , Simon Matthias , Brüstle Oliver , Steindler Dennis A. , Scheffler Björn
Published: April 2023

Control arms for Fig. 6 experiments AND Potential future approaches.
Supplementary Table 1 and 2 from First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Authors: Munster Pamela , Aggarwal Rahul , Hong David , Schellens Jan H.M. , van der Noll Ruud , Specht Jennifer , Witteveen Petronella O. , Werner Theresa L. , Dees E. Claire , Bergsland Emily , Agarwal Neeraj , Kleha Joseph F. , Durante Michael , Adams Laurel , Smith Deborah A. , Lampkin Thomas A. , Morris Shannon R. , Kurzrock Razelle
Published: April 2023

Supplementary Table 1. Pharmacokinetic Parameters on Day 1 Following Once daily and Twice Daily Administration of GSK458 Supplementary Table 2. Best Objective Tumor Response by Dose Level (supplementary)
Supplemental table 2 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

Correlations between expression status of pEGFR, pSTAT3, CEBPD, and ABCB1 in muscle invasive UCUB in our independent cohort containing 60 patients receiving post-operative chemotherapy
Supplemental table 1 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

Correlations between CEBPD expression and other important clinicopathological parameters in 79 muscle invasive UCUB receiving post-operative chemotherapy
Supplemental Figure 7 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

Expression and activities of EGFR and STAT3 levels in UCUB cells. Western blot analysis was conducted with lysates from UCUB cells. TSGH8301 (TSG), TCCSUP (TCC), NTUB1 (NTU) and CDDP resistance NTUB1/P (NTP).
Supplemental Figure 4 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

Gefitinib and S3I-201 attenuate ABCB1 transcripts of and enhance CDDP sensitivity of J82 cells. A, cells were treated with CDDP alone or in combination with gefitinib or S3I-201 for 24 h. A qPCR assay was conducted with specific primers for ABCB1 gene. ***, significant difference (P < 0.001). B, J82 cells were then transfected with ABCB1 reporter (-21~+917) (AB-I, as shown in Fig. 3D) and treated with CDDP alone or in combination with gefitinib or S3I-201. After 24 h. A Luciferase assay was conducted using lysates of transfectants. ***, significant difference (P < 0.001). C, gefitinib and S3I-201 attenuate ABCB1 pump activity and enhance CDDP sensitivity of J82 cells. J82 cells were treated with CDDP alone or CDDP combining gefitinib or S3I-201 for 24 h, MDR dye-loading solution was added to each well for 4 h, and fluorescence intensities were detected by ELISA reader. ***, significant difference (P < 0.001). D, J82 cells were treated with CDDP alone or CDDP combining gefitinib or S3I-201 for 24 h. Death of experimental cells was examined by PI staining. ***, significant difference (P < 0.001). E, CEBPD contributes to drug resistance of cisplatin (CDDP) in nasopharyngeal carcinoma HONE1/R (CDDP-resistant HONE) cells. HONE1/R cells were resistant to CDDP treatment. HONE1 and HONE1/R cells were treated with CDDP in dose-dependent manner. Cell viability was examined by CCK8 assay. *, significant difference (P < 0.05). **, significant difference (P < 0.01). ***, significant difference (P < 0.001). F, CDDP induces expression of CEBPD and ABCB1. HONE1/R cells were treated with CDDP for 24 h and then lysates of experimental cells were analyzed by Western blot. G, HONE1/R cells were treated with gefitinib, S3I-201 or CDDP or in combination as indicated for 24 h, MDR dye-loading solution was added to each well for 4 h and fluorescence intensities were detected by ELISA reader. ***, significant difference (P < 0.001). H, S3I-201 enhances sensitivity of CDDP in HONE1/R cells. HONE1/R cells were treated with CDDP (20 μM) alone or in combination with S3I-201 (100 μM) for 24 h and death of experimental cells was examined by PI staining. ***, significant difference (P < 0.001).
Supplemental Figure 3 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

Overexpression of CEBPD upregulates ABCB1 and ABCC2 transcription in CDDP-resistant NTUB1/P (NTP) cells. A, RT-PCR assay was conducted with total RNA harvested from NTP cells transfected with pCDNA3/HA/CEBPD expression vectors. B, overexpression of CEBPD upregulates ABCB1 transcription containing known exon 1 (NM_000927.4) in CDDP-resistant NTP cells. RT-PCR assay was conducted with total RNA harvested from NTP cells transfected with pCDNA3/HA/CEBPD expression vectors. Upper panel shows location of forward primer (+159) in exon 1 and reverse primer (+348) in exon 2 of ABCB1 gene locus.
Figure S2 from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

Combination Index (CI) presented as a function of Fraction Affected (Fa) for cell lines tested by DIMSCAN analysis.
Supplementary Table 2 from Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Authors: Okada Hideho , Butterfield Lisa H. , Hamilton Ronald L. , Hoji Aki , Sakaki Masashi , Ahn Brian J. , Kohanbash Gary , Drappatz Jan , Engh Johnathan , Amankulor Nduka , Lively Mark O. , Chan Michael D. , Salazar Andres M. , Shaw Edward G. , Potter Douglas M. , Lieberman Frank S.
Published: April 2023

Supplementary Table 2. Comparison of ELISPOT responses between the current study and our recent study in pediatric glioma patients
Supplementary Figures 1-3, Supplementary Tables 1-2, Supplementary Information 1-2 from Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer
Authors: Xu Lai , Ziegelbauer Joseph , Wang Rong , Wu Wells W. , Shen Rong-Fong , Juhl Hartmut , Zhang Yaqin , Rosenberg Amy
Published: April 2023

Table S1. Tumor sample and patient information; Table S2a. 9 upregulated MT-tRNAs; Table. S2b. 13 upregulated snoRNAs; Table. S2c. 19 downregulated snoRNAs; Table S3: CRC tumor fingerprint based on T/N PRKM ratio (1); Figure S1. RPKMs of snord12 cluster (a) and snord114 cluster (b) were plotted in 35 CRC pairs; Fig. S2. (a) 3D PCA of 22 MT-tRNAs (RPKM) in 35 CRC pairs; Fig. S3. Nine regulated MT-tRNAs (a), 13 upregulated (b) and 19 downregulated snoRNAs (c) were plotted by their RPKMs in 35 CRC pairs; Fig. S4. (a) Top twenty sRNAs with smallest p-values (paired t-test) in all 35 CRCs. (b) All examined 14 tumors had higher expression of ZNFX1-AS1 (host gene of snord12 cluster). (c) Expression correlation between snord12B and ZNFX1-AS1 in 14 tumors; Fig. S5. snord1114 cluster (a) and MEG3 (b) were plotted by their RPKM in 14 CRC pairs; Supplementary information (S1) Fidelity of RNA-Seq analysis and identification of house keeping genes; Supplementary information S2. Correlation between MT-tRNAs and miRNAs.
Supplementary Figure 2 from Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Authors: Okada Hideho , Butterfield Lisa H. , Hamilton Ronald L. , Hoji Aki , Sakaki Masashi , Ahn Brian J. , Kohanbash Gary , Drappatz Jan , Engh Johnathan , Amankulor Nduka , Lively Mark O. , Chan Michael D. , Salazar Andres M. , Shaw Edward G. , Potter Douglas M. , Lieberman Frank S.
Published: April 2023

Supplementary Figure 2. Immunohistochemistry evaluating expression of vaccine-targeted antigens in resected tumor tissues.
Supplementary Figure 1 from Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Authors: Okada Hideho , Butterfield Lisa H. , Hamilton Ronald L. , Hoji Aki , Sakaki Masashi , Ahn Brian J. , Kohanbash Gary , Drappatz Jan , Engh Johnathan , Amankulor Nduka , Lively Mark O. , Chan Michael D. , Salazar Andres M. , Shaw Edward G. , Potter Douglas M. , Lieberman Frank S.
Published: April 2023

Supplementary Figure 1. T2-Flair MRI images of 2 cases (Patient 9 in Cohort 1 and Patient 1 in Cohort 2)
Supplementary Figure Legends from Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Authors: Cristóbal Ion , Rincón Raúl , Manso Rebeca , Caramés Cristina , Zazo Sandra , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 2 from Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Authors: Eaton Anne , Iasonos Alexia , Gounder Mrinal M. , Pamer Erika G. , Drilon Alexander , Vulih Diana , Smith Gary L. , Ivy S. Percy , Spriggs David R. , Hyman David M.
Published: April 2023

Histograms of physician attribution (5-tier scale) of all grade {greater than or equal to}3 toxicities by toxicity category. On the attribution scale (x axis), 1 represents 'unrelated', 2 represents 'unlikely related', 3 represents 'possibly related', 4 represents 'probably related', and 5 represents 'definitely related'.
Supplementary Figures 1 - 2 from A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Authors: Garcia-Manero Guillermo , Khoury Hanna J. , Jabbour Elias , Lancet Jeffrey , Winski Shannon L. , Cable LouAnn , Rush Selena , Maloney Lara , Hogeland Grant , Ptaszynski Mieke , Calvo Monica Cabrero , Bohannan Zach , List Alan , Kantarjian Hagop , Komrokji Rami
Published: April 2023

Figure S1. EPO and plasma chemokine expression following treatment with ARRY-614 at 1200 mg QD. Figure S2. Comparison of EPO in IWG2006 Responders and Non-Responders.
Supplemental table 1 from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Authors: Hansson Markus , Gimsing Peter , Badros Ashraf , Niskanen Titti Martinsson , Nahi Hareth , Offner Fritz , Salomo Morten , Sonesson Elisabeth , Mau-Sorensen Morten , Stenberg Yvonne , Sundberg Annika , Teige Ingrid , Van Droogenbroeck Jan , Wichert Stina , Zangari Maurizio , Frendeus Björn , Korsgren Magnus , Poelman Martine , Tricot Guido
Published: April 2023

Supplemental table 1. Bone marrow BI-505 concentration and MM-cell ICAM-1 expression
Supplemental Table 2 from Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
Authors: Sinicrope Frank A. , Mahoney Michelle R. , Yoon Harry H. , Smyrk Thomas C. , Thibodeau Stephen N. , Goldberg Richard M. , Nelson Garth D. , Sargent Daniel J. , Alberts Steven R.
Published: April 2023

Supplemental Table 2. Multivariate Cox Models (DFS, OS, and TTR)